Industry

–Forte Biosciences to Develop Novel Pipeline for the Treatment of Autoimmune Diseases– -Leadership Strengthened with Appointments of Stephen Doberstein, Ph.D. and Barbara Finck, M.D. to the Board of Directors- -Ended first quarter 2022 with approximately $40.0 million in cash and cash equivalents- DALLAS–(BUSINESS WIRE)–Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune … [Read more…]

— Company Continues to Successfully Advance Product Candidates — BERWYN, Pa.–(BUSINESS WIRE)–#earnings—Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2022, and other recent developments. “We continue to make excellent progress with all of our drug product candidates,” stated Anthony P. Mack, Chairman and Chief … [Read more…]

PARSIPPANY, N.J.–(BUSINESS WIRE)–IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will present a corporate overview at the H.C. Wainwright Global Investment Conference, being held from May 23-26, 2022. The on-demand presentation will be available for viewing beginning Tuesday, May 24 at 7:00 a.m. ET and can be accessed on the … [Read more…]

ANN ARBOR, Mich.–(BUSINESS WIRE)–$NDRA #NALFD—ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, announces that management will present a company overview at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami Beach and will be holding virtual one-on-one meetings. A webcast of the presentation will be available on-demand … [Read more…]

Poster to highlight lead therapeutic candidates, a series of fully personalized T cell therapies WATERTOWN, Mass.–(BUSINESS WIRE)–RootPath, a synthetic biology company that elevates the throughput of gene function interrogation by orders of magnitude, today announced that a poster presentation highlighting its lead therapeutic candidates, a series of fully personalized T cell therapies, at the American … [Read more…]

– Results from pharmacokinetic (PK) similarity study demonstrate bioequivalence of AVT04 (ustekinumab) to the reference product Stelara® REYKJAVIK, Iceland–(BUSINESS WIRE)–Alvotech Holdings S.A. (“Alvotech”), a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, today announced positive top-line results from a pharmacokinetic (PK) study for AVT04, Alvotech’s proposed biosimilar … [Read more…]

Latest addition to Company’s genomic testing services menu delivers rapid results to physicians that inform clinical management and outcomes for critically ill patients WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the availability of ultrarapid whole genome sequencing (urWGS) through PerkinElmer Genomics. This addition to the Company’s … [Read more…]

Phase IIb NASH study is currently enrolling patients; Phase IIa met endpoints including reduced liver fat content PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that its patent titled “An A3 Adenosine … [Read more…]

Trial-in-progress poster of Phase 1/2 CEDAR trial evaluating GPH101 for sickle cell disease to be presented as an encore SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today … [Read more…]

New compounds specifically inhibit NLRP3 in mouse models and human cells Series includes orally active small molecules capable of crossing the blood–brain barrier, enabling their use in treating neuroinflammation RICHMOND, Calif.–(BUSINESS WIRE)–BioAge Labs, Inc. (“BioAge”, “the Company”), a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today … [Read more…]